

Table SI. Definition of time periods

Time period	Constant treatment groups			
	Placebo	Ustekinumab	Brodalumab 140 mg Q2W	Brodalumab 210 mg Q2W
Period 1: baseline until discontinuation, treatment switch or week 12, whichever comes first				
Period 2: baseline until rescue, discontinuation, treatment switch or week 52, whichever comes first		Ustekinumab	Brodalumab 140 mg Q2W	Brodalumab 210 mg Q2W
Period 3: baseline until rescue, discontinuation, treatment switch or EOT, whichever comes first			Brodalumab 140 mg Q2W	Brodalumab 210 mg Q2W
Period 4: baseline until rescue, discontinuation, treatment switch or EOT, including follow-up period, whichever comes first			Brodalumab 140 mg Q2W	Brodalumab 210 mg Q2W

EOT: end of treatment; Q2W: every 2 weeks.